CD274 and Hodgkins lymphoma: Drugs targeting the PD1/PD-L1 axis such as the anti-PD1 antibodies nivolumab and pembrolizumab have demonstrated outstanding efficacy in relapsed/refractory (r/r) HL, and are approved in this setting [4–6].